Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Fallopian Tube Undifferentiated Carcinoma"
Page 1
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J. Newhouse R, et al. Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3. Cochrane Database Syst Rev. 2023. PMID: 37407274 Review.
BACKGROUND: Cancer of ovarian, fallopian tube and peritoneal origin, referred to collectively as ovarian cancer, is the eighth most common cancer in women and is often diagnosed at an advanced stage. ...MAIN RESULTS: This is an update of a previous review with 12 ad …
BACKGROUND: Cancer of ovarian, fallopian tube and peritoneal origin, referred to collectively as ovarian cancer, is the eighth …
Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G, El-Khouly F, Dilley J. Zachou G, et al. Cochrane Database Syst Rev. 2023 Aug 31;8(8):CD006119. doi: 10.1002/14651858.CD006119.pub4. Cochrane Database Syst Rev. 2023. PMID: 37650760 Review.
MAIN RESULTS: For this update, we included one new RCT, including 112 women with ovarian, fallopian tube, or peritoneal cancer, who had completed primary treatment by surgery, with or without chemotherapy. ...
MAIN RESULTS: For this update, we included one new RCT, including 112 women with ovarian, fallopian tube, or peritoneal cancer …
Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN. Van der Hoeven NMA, et al. Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22. Clin Oncol (R Coll Radiol). 2018. PMID: 29691126
The prevalence of occult carcinoma and STIC in a consecutive series of BRCA1/2 carriers undergoing RRSO is reported. ...We found 1.3% occult carcinoma and 0.9% STIC at RRSO in our cohort of BRCA1/2 carriers. ...
The prevalence of occult carcinoma and STIC in a consecutive series of BRCA1/2 carriers undergoing RRSO is reported. ...We found 1.3% …
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH. Piedimonte S, et al. Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702. Obstet Gynecol. 2020. PMID: 32028491
OBJECTIVE: To perform a systematic review of the literature to estimate the prevalence and outcomes of occult tubal carcinoma in BRCA mutation carriers and high-risk patients undergoing risk-reducing salpingo-oophorectomy. ...CONCLUSION: Occult tubal carcinomas found at ri …
OBJECTIVE: To perform a systematic review of the literature to estimate the prevalence and outcomes of occult tubal carcinoma in BRCA …
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T. Auer RC, et al. Eur J Cancer. 2020 Mar;127:76-95. doi: 10.1016/j.ejca.2019.10.034. Epub 2020 Jan 24. Eur J Cancer. 2020. PMID: 31986452
For patients with newly diagnosed, primary stage III epithelial ovarian, fallopian tube or primary peritoneal carcinoma, HIPEC with CRS should be considered for those with at least stable disease following neoadjuvant chemotherapy at the time of interval CRS …
For patients with newly diagnosed, primary stage III epithelial ovarian, fallopian tube or primary peritoneal carcinoma …
Extra-abdominal ovarian cancer presenting with breast metastases at diagnosis: Case report and literature review.
Ferrari F, Ficarelli S, Forte S, Valenti G, Ardighieri L, Sartori E, Odicino F. Ferrari F, et al. Eur J Obstet Gynecol Reprod Biol. 2020 Dec;255:211-221. doi: 10.1016/j.ejogrb.2020.10.004. Epub 2020 Oct 12. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 33152565
RESULTS: According to the search strategy, 16 articles (18 patients) were included in this review. Serous ovarian, fallopian tube or primary peritoneal cancer was detected in 61% of cases, while another type or a non-specified type of epithelial ovarian cancer was d …
RESULTS: According to the search strategy, 16 articles (18 patients) were included in this review. Serous ovarian, fallopian tube …